Nov 2021; Primum iudicium clinicum Coreae Meridianae domesticae proximo-generationis chimaericae antigen receptoris T (CAR-T) therapiae cellulae, quae destinatur ad LAPIS immunes circumveniendi significationibus, nuper obvia est.
Corea Provectus Institutum Scientiae et Technologiae (KAIST) die Mercurii denuntiavit Phase 1b clinicum experimentum sui CAR-T cellae therapiae nunc perduci ad Samsung Medical Centrum in Seoul. Iudicium perducitur cum aegros Coreanis 10 qui relapsos et refractores magnas lymphoma B cellae diffundunt. Iura venalicium pro pipelino ex universitate ad societatem Curocell translata sunt, quae a Professore Kim Chan-hyuk co condita est. Curocell praepositus est programmatis evolutionis clinicae rerum novarum immunotherapy.
In addition, a Phase 2 orci iudicio involving seventy participants is going to take place the following year to assess how safe and effective the investigational medication is.
The acronym CAR T, which stands for antigen receptor chimaricus T, is frequently referred to as a miracle cure. This is due to the fact that studies conducted in other countries on terminal blood cancer patients demonstrated that the therapy had a therapeutic effect of more than 80 percent. T cells from a patient are taken from the patient’s blood, genetically enhanced to make them more effective, and then reintroduced to the patient so that they can continue to fight and destroy cancer cells inside the patient’s body.
The research team that was led by Professor Kim of the Department of Biomedical Engineering at the KAIST confirmed an improved anticancer efficacy of CAR-T cells in mice with leukaemia and lymphoma. This was achieved by simultaneously inhibiting programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and ITIM domain (TIGIT), both of which are known to disturb the function of T cells. According to Professor Lee Young-ho, a post-doctoral researcher at KAIST and the first author of the animal model study, this dual blockade of PD-1 and TIGIT is a novel strategy to overcome the immunosuppression of existing CAR-T cells. This strategy was discovered by Prof. Lee Young-ho.
Ut legere licet: CAR T-Cell Lorem in Korea
Inventiones studiorum praesentatae sunt in articulo qui in online mense Octobri quaestio Therapy Molecularis edita est.
